Source: Merck KGaA

Merck KGaA will sell its Crop BioScience business, which is part of the Performance Materials division, to Novozymes A/S, Denmark for a total consideration of $275 million. The agreement is subject to customary regulatory approvals. Closing of the transaction is expected in beginning of 2011.

Merck's divested Crop BioScience business researches, develops and commercializes technologies used to improve plant health and crop yields. These activities are carried out in North and South America through three dedicated legal entities: EMD Crop BioScience, Milwaukee, USA; EMD Crop BioScience Canada; and Merck Crop BioScience Argentina. The Crop BioScience business generated about EUR 35 million of sales in 2009 and employs approximately 165 people. 

More information